2026-06-18 · 2026-06 / week-3
FICO Prices the Debt, Not the Denominator
FICO Prices the Debt, Not the Denominator
Summary: FICO (FICO) closed at $1,126.84 on 2026-06-17 20:00:03 UTC, down 5.0% from the prior close, even after the company had already announced a $2.0 billion repurchase authorization, a $1.5 billion incremental term loan, and a $1.5 billion accelerated share repurchase with initial delivery of about 1,055,100 shares.[1][2] The market is right to charge FICO for leverage and regulatory risk. It is wrong if it treats the June financing as a vague authorization. The ASR is funded, signed, and expected to finish by 2026-09-30.[1]
Scope note: this run was explicitly limited to U.S. market long opportunities. Before selection, I scanned the current target folder articles/2026-06/week-3/, ran a repo-wide title and slug cross-check, and checked automation memory. I rejected duplicate or recently used U.S.-long lanes including NEO, PTRN, OLN, UNCY, ADBE, QMCO, HGV, SIG, LFST, and BTSG. Creative search lanes used in this run included site:sec.gov June 2026 accelerated share repurchase term loan price dislocation, site:sec.gov June 2026 exchangeable notes common stock repurchase, site:sec.gov June 2026 share repurchase authorization stock down 52 week low, and site:sec.gov June 2026 final tender offer stock still below mechanics.
Opportunity Ranking
| Rank | Idea | Discovery Lane | Why It May Be Best Now | Evidence Freshness | Catalyst Window | Near-Term >5% Move Case | Asymmetry | Main Reason to Reject |
|---|---|---|---|---|---|---|---|---|
| 1 | Long FICO (FICO) |
U.S. large-cap / debt-funded ASR / oversold quality compounder | The stock sold off 5.0% on 2026-06-17 while the company has already funded a $1.5 billion ASR, received initial delivery of about 1.055 million shares, and raised FY2026 revenue, GAAP EPS, and non-GAAP EPS guidance in April.[1][2][3] | High: quote checked after the June 17 close; ASR filing dated June 8; Q2 earnings release and 10-Q filed April 28. | ASR settlement expected by 2026-09-30; any stabilization above the June 5 low can force a near-term rerating. | From $1,126.84, a move to $1,183.18 is +5.0%. That is below the $1,186.24 close from June 16 and inside the last week's trading range.[2] | Strong. The downside is real if leverage or credit-score regulation dominates, but the denominator shrink is already in motion. | Selected. |
| 2 | Long Innovative Industrial Properties (IIPR) |
U.S. REIT / exchangeable-note cleanup / share repurchase | IIPR closed at $58.65 after issuing $402.5 million of 6.00% exchangeable notes and repurchasing 1,334,466 shares at $60.34. The exchange price is about $69.39.[4][8] | High: note issuance closed June 15; quote checked June 17. | Note close has occurred; rerating depends on market accepting the capital stack. | A rebound to $61.58 is +5%, close to the June 11 close of $61.77.[8] | Moderate. | Rejected because tenant-default risk and cannabis credit stress are not misread noise. They are central to the equity. |
| 3 | Long BitGo (BTGO) |
U.S. recent IPO / crypto infrastructure / fresh buyback | BitGo authorized up to $50 million of common-stock repurchases, described as about 8% of Class A shares outstanding, funded from existing cash and ongoing cash flow.[6] | High: 8-K dated June 17; quote checked June 17. | Immediate authorization with no fixed expiry. | From $5.91, a move to $6.21 is +5.1%; the stock is still far below its $24.50 52-week high.[9] | Potentially strong, but more speculative. | Rejected because the buyback is discretionary, the Q1 adjusted EBITDA was negative, and the stock already jumped 8.6% on the headline.[6][7][9] |
Selected opportunity: Long FICO (FICO)
Why this one now: FICO combines a fresh mechanical catalyst with a quality business that just raised guidance. This is not a story about a board saying it may buy stock someday. The company drew a $1.5 billion term loan, paid that amount into an ASR, and expected immediate delivery of about 1.055 million shares.[1]
Why it can jump more than 5% soon: The stock only needs to retrace the June 17 selloff. A +5% move from $1,126.84 is $1,183.18, still below the prior day's close of $1,186.24 and inside the June 8 to June 16 trading range.[2]
What should surprise the reader: The non-consensus point is that the debt headline is easier to see than the denominator math. At the March 31 share count of 23.295 million, the initial ASR delivery alone equals about 4.5% of shares outstanding before any final settlement shares.[1][5]
The Setup
FICO is a strange long because the obvious bear case is not stupid. The company had $3.639 billion of long-term debt and $219.4 million of cash at March 31, 2026.[5] It then drew another $1.5 billion term loan to fund an ASR.[1] A skeptical trader can say leverage is rising at the same time regulators, lenders, and consumer-credit politics keep circling the FICO score franchise.
That is the strongest version of the short case. It is also why the opportunity exists.
The April quarter was not weak. FICO reported $691.7 million of revenue, up 39% year over year, with Scores revenue up 60% to $475.0 million and Software revenue up 7% to $216.7 million.[3] GAAP net income was $264.5 million, operating cash flow was $223.4 million, and free cash flow was $214.3 million.[3] Management raised FY2026 guidance to $2.45 billion revenue, $35.60 GAAP EPS, and $40.45 non-GAAP EPS.[3]
Then, on June 8, FICO announced a new $2.0 billion repurchase authorization and a $1.5 billion ASR funded by a term loan drawn on June 5.[1] The initial share delivery was expected to be about 1,055,100 shares, with final settlement by the end of fiscal 2026 on September 30, 2026.[1]
The stock closed at $1,126.84 on June 17, near the lower end of its recent range and only about 29.5% above the $870.01 52-week low shown by Yahoo Finance.[2] The market is pricing the debt and regulatory overhang faster than the denominator shrink.
The Mispricing
The mispricing is specific: FICO is being treated like a levered governance choice, while the filings show an already-activated repurchase mechanism against a business still compounding revenue and cash flow.
Facts: the ASR received a $1.5 billion upfront payment and was expected to deliver about 1.055 million shares initially.[1] FICO had 23.295 million common shares outstanding at March 31.[5] Q2 free cash flow was $214.3 million, and FY2026 non-GAAP EPS guidance was raised to $40.45.[3]
Inference: the market is overweighting the financing wrapper and underweighting the share-count effect because the buyback is paired with debt rather than funded entirely from existing cash.
Speculation: some of the June 17 selling may reflect a risk-off rotation away from expensive compounders or renewed concern about credit-score pricing scrutiny. I did not verify a single news item on June 17 that fully explains the move.
Why the market may be wrong: a debt-funded ASR can be dangerous when it funds financial engineering over a weak base. That is not this fact pattern. The underlying quarter was strong, guidance moved up, and the share delivery is not hypothetical.
Why the market may be right: FICO is not cheap. At $1,126.84, it trades at about 27.9x FY2026 non-GAAP EPS guidance of $40.45 and about 31.7x GAAP EPS guidance of $35.60.[2][3] If investors lower the acceptable multiple because of leverage or regulatory risk, the buyback may only cushion the fall.
Price
| Item | Value | Timestamp | Source | Why it matters |
|---|---|---|---|---|
| FICO close | $1,126.84 | 2026-06-17 20:00:03 UTC | Yahoo Finance chart API [2] | Current entry reference |
| Prior close | $1,186.24 | 2026-06-16 | Yahoo Finance chart API [2] | Shows the one-day gap that a 5% rebound would nearly retrace |
| One-day move | -5.0% | 2026-06-17 | Author calculation from Yahoo Finance chart API [2] | Fresh dislocation |
| 52-week range | $870.01 to $1,998.01 | Checked 2026-06-18 05:05 +07 | Yahoo Finance chart API [2] | Shows the stock remains deeply reset from its high |
| Approximate RSI(14) | 30.2 | Checked 2026-06-18 05:05 +07 | Author calculation from Yahoo daily closes [2] | Technical timing input only |
| New repurchase authorization | $2.0 billion | Announced 2026-06-08 | FICO 8-K exhibit [1] | Capital-return capacity |
| ASR upfront payment | $1.5 billion | Announced 2026-06-08 | FICO 8-K exhibit [1] | Mechanism already funded |
| Initial ASR delivery | About 1,055,100 shares | Expected 2026-06-08 | FICO 8-K exhibit [1] | Immediate denominator effect |
| ASR expected completion | By 2026-09-30 | FICO fiscal year-end | FICO 8-K exhibit [1] | Dated catalyst |
| Q2 revenue | $691.7 million, up 39% | Quarter ended 2026-03-31 | FICO Q2 release [3] | Operating support |
| Q2 free cash flow | $214.3 million | Quarter ended 2026-03-31 | FICO Q2 release [3] | Debt service and repurchase support |
| FY2026 non-GAAP EPS guidance | $40.45 | Updated 2026-04-28 | FICO Q2 release [3] | Valuation anchor |
| Cash | $219.4 million | 2026-03-31 | FICO 10-Q company facts [5] | Balance-sheet anchor before the new term loan |
| Long-term debt | $3.639 billion | 2026-03-31 | FICO 10-Q company facts [5] | Leverage risk before the new term loan |
| Shares outstanding | 23.295 million | 2026-03-31 | FICO 10-Q company facts [5] | Denominator for ASR impact |
The technical signal is a timing input, not the thesis. The article still works without RSI because the real disagreement is between a visible share-count reduction and the market's debt-first reaction.
Positioning
I did not verify live short interest, borrow cost, dealer gamma, or options open interest for FICO in this run. That limits the positioning claim.
What is supported:
- The tape is reset. FICO is well below its $1,998.01 52-week high and now close to the recent June lows.[2]
- The reaction is asymmetric to the filing. The ASR announcement on June 8 produced a rebound to $1,207.34, but by June 17 the stock was back to $1,126.84 despite the ASR mechanics remaining in force.[1][2]
- Quality investors may be under pressure. This is an inference, not a verified holder-flow fact. Expensive compounders with new leverage can be sold first when the market wants lower duration.
Missing data: I did not verify fund flows, 13F changes after the announcement, live lending data, or option skew. The article should not pretend those facts are known.
Catalyst
The catalyst path is mechanical and dated.
First, the ASR has already started. FICO expected initial delivery of about 1.055 million shares on June 8.[1] That is not the same as a board authorization with no execution.
Second, the final ASR share count will be based on the volume-weighted average price during the ASR period, less a discount and subject to customary adjustments.[1] Lower share prices during the period can increase final share retirement, which creates a reflexive cushion if the business remains intact.
Third, the expected completion date is by September 30, 2026.[1] That gives the market a finite window to reconcile leverage fear with the actual denominator reduction.
What accelerates the thesis: visible stabilization above the $1,137 to $1,186 June range, management commentary that debt service remains comfortable, or new evidence that mortgage-score volume and pricing remain resilient.
What delays the thesis: the market continuing to value FICO primarily as a regulatory-risk asset rather than an earnings compounder.
What kills the thesis: a credible regulatory or customer-pricing development that compresses the Scores economics faster than the ASR can offset.
Payoff Map
This is a long common-stock idea.
- Fact: FICO funded a $1.5 billion ASR and expected initial delivery of about 1.055 million shares.[1]
- Fact: the company raised FY2026 revenue, GAAP EPS, and non-GAAP EPS guidance in April.[3]
- Inference: the June 17 close is pricing the financing wrapper too harshly relative to the already-started denominator shrink.
- Trade expression: long
FICOcommon stock. Options are not preferred because I did not verify a live chain, implied volatility, or skew.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff | Time Horizon | Conditions Required | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 30% | $1,300 | +15.4% | 1 to 3 months | The market refocuses on the raised FY2026 guide, accepts the ASR as real denominator shrink, and the stock reclaims late-May levels. | Medium |
| Base Case | 45% | $1,215 | +7.8% | 2 to 8 weeks | The June 17 drop reverses, ASR mechanics remain the focus, and the multiple stabilizes near the June 8 to June 16 range. | High |
| Bottom Case | 25% | $1,020 | -9.5% | 1 to 3 months | Leverage and regulatory risk dominate, quality-duration selling continues, or the market assigns a lower multiple despite repurchases. | Medium |
| Invalidation / Stop Condition | n/a | Below $1,060 on no new company-specific evidence | Thesis break, not a trade instruction | During the ASR window | A sustained break below the June lows would imply the market is discounting more than transient financing concern. | Medium |
Probability-weighted expected value: $1,183.25, or about +5.0% versus $1,126.84.
Current market price / level: $1,126.84
Timestamp: 2026-06-17 20:00:03 UTC
Primary instrument: FICO common stock
Alternative expressions considered: IIPR common after exchangeable-note close, BTGO common after fresh buyback authorization, and FICO call options. IIPR has a cleaner financing document but a messier tenant-credit debate. BTGO has a fresher headline but a weaker operating base. FICO call options were rejected because live chain data were not verified.
Confidence: Medium
What Would Prove This Wrong
The cleanest kill shot is regulation. If policymakers, customers, or the courts force a pricing model that structurally lowers Scores economics, the ASR becomes a smaller denominator on a lower-quality earnings stream. That would not be a timing miss. It would be thesis failure.
The second kill shot is leverage. FICO ended March with $3.639 billion of long-term debt and then added a $1.5 billion term loan.[1][5] If investors decide that the company has transferred too much balance-sheet value from creditors to equity holders, the multiple can compress faster than share count falls.
The third kill shot is hidden cyclicality. Q2 Scores revenue benefited from mortgage origination volume and higher mortgage origination scores unit price.[3] If that revenue proves less durable than the market currently assumes, the raised guidance becomes a stale anchor.
Risk Audit
Strongest counterargument: FICO is using debt to buy back expensive stock while the regulatory target on credit-score economics grows larger. A lower multiple can overwhelm the share-count reduction.
Most fragile assumption: The Scores franchise remains economically durable enough that a debt-funded ASR is accretive rather than reckless.
What the market may already know: The repurchase authorization, term loan, ASR structure, and initial share delivery are all public.[1]
What could make the trade lose money even if the thesis is directionally right: timing and multiple compression. The ASR can be real, and the stock can still fall if investors lower the acceptable leverage-adjusted multiple.
Liquidity / execution risks: FICO is liquid enough for ordinary common-stock expression, but the share price is high and daily moves can be large. June 17 volume was 327,246 shares.[2]
Leverage risks: Material. The company had $3.639 billion of long-term debt at March 31 before the new term loan.[1][5]
Information reliability risks: Strong on filings, market price, and reported financials. Weak on live short interest, options positioning, and June 17 seller identity.
Invalidation trigger: Sustained trade below $1,060 without a broad-market explanation, or any concrete regulatory development that lowers the expected Scores earnings base.
Publish / revise / reject recommendation: Publish as a Deep Dive Trade Note with medium confidence.
Best Trade Strategy
| Item | View |
|---|---|
| Direction | Long |
| Preferred instrument | FICO common stock |
| Common-stock stance | Best expression. The thesis is about share-count shrink and business quality, not a short-dated binary event. |
| Options stance | Not preferred. Insufficient live option-chain and implied-volatility data in this run. |
| TP | Base-case $1,215. Top-case $1,300. |
| SL or invalidation | Thesis weakens below $1,060, especially if the move is company-specific and not broad-market driven. |
| Timeline | 2 to 8 weeks for the base case; up to 3 months for the fuller ASR recognition. |
| Execution risks | Large nominal share price, high-duration multiple risk, leverage headline risk, and regulatory news risk. |
| Do-not-trade conditions | Do not trade if fresh regulatory evidence directly impairs Scores economics. Do not use options without live chain verification. Do not chase above $1,300 unless new evidence raises the earnings base. |
| Monitoring checklist | Watch ASR updates, debt commentary, mortgage-score volume, regulatory headlines on credit-score pricing, price behavior around $1,183, and any break below $1,060. |
| Sourced live prices or missing-data notes | Live price reference is Yahoo Finance chart API checked after the 2026-06-17 close.[2] Borrow, short-interest, and options-liquidity data were not verified. |
Bottom Line
FICO is not a cheap stock. That is not the thesis. The thesis is that the market is charging the stock for debt while undercounting an already-funded ASR and a raised earnings base. The June 17 selloff creates a clean long common-stock setup because a 5% rebound only puts the stock back near the prior close, while the denominator clock keeps running through fiscal year-end.
Research Quality Scorecard
| Criterion | Score | Why |
|---|---|---|
| Market disagreement | 5 | The disagreement is clear: debt headline and regulatory fear versus already-funded denominator shrink. |
| Evidence base | 5 | Fresh market price, SEC filings, Q2 earnings release, and company facts support the core claims. |
| Positioning and flows | 3 | Price reset and volume are verified, but live short, borrow, and option data are missing. |
| Catalyst path | 5 | The ASR has started and is expected to settle by 2026-09-30. |
| Payoff architecture | 4 | Top, base, bottom, EV, and invalidation are defined. |
| Invalidation discipline | 5 | Regulatory, leverage, and price-break triggers are explicit. |
| Differentiated insight | 4 | The focus is on denominator mechanics rather than generic quality-compounder dip buying. |
| Client value | 4 | Useful even without a trade because it separates debt-funded engineering from a funded ASR on a strong earnings base. |
Total score: 35 / 40
Publish decision: Publish
Section 17 Quality Gate
| Question | Answer | Note |
|---|---|---|
| 1. Is the mispricing specific? | Yes | Debt/regulatory fear versus funded ASR denominator shrink. |
| 2. Is there evidence beyond narrative? | Yes | SEC filing, Q2 release, 10-Q facts, and live quote are sourced. |
| 3. Is the positioning claim supported or clearly labeled as uncertain? | Yes | Missing short, borrow, and options data are explicit. |
| 4. Is there a catalyst or plausible closing mechanism? | Yes | ASR expected completion by 2026-09-30. |
| 5. Is the downside case described honestly? | Yes | Regulation, leverage, and multiple compression are central risks. |
| 6. Is the strongest counterargument included? | Yes | Debt-funded buyback at a high multiple under regulatory pressure. |
| 7. Is the article useful even if the trade is not taken? | Yes | It gives a framework for reading funded ASRs. |
| 8. Are all factual claims sourced or marked as unverified? | Yes | Unverified flows and options are labeled. |
| 9. Does the article avoid hype? | Yes | Yes. |
| 10. Does the headline match the actual evidence? | Yes | The article is about debt fear versus denominator shrink. |
| 11. Does the article explain why this is the best opportunity right now? | Yes | Ranking and rejection reasons are included. |
| 12. Does the article explain why the selected asset can plausibly jump or dump more than 5% soon, including direction, trigger, timeframe, and evidence quality? | Yes | $1,126.84 to $1,183.18 is a near-retrace during the active ASR window. |
| 13. Does the article identify what should surprise a sophisticated reader? | Yes | Initial ASR delivery equals about 4.5% of March shares outstanding. |
| 14. Does the article include top, base, and bottom targets with probabilities that add to 100%? | Yes | 30 / 45 / 25. |
| 15. Does the main article file include its Research Quality Scorecard in a dedicated section? | Yes | Included above. |
| 16. Are all reader-facing tables kept as Markdown tables in the main article file? | Yes | Yes. |
| 17. If optional table images were explicitly requested, are they saved as separate packaging artifacts without replacing the main article Markdown tables? | N/A | None requested. |
18. If the task required an illustration prompt, is it included inline in the main article file rather than a separate file, with a subtle The Mispricing Desk watermark requirement? |
Yes | Included below. |
19. Does the main article file include a Best Trade Strategy section with direction, preferred instrument, common-stock stance, options stance, TP, SL or invalidation, timeline, execution risks, do-not-trade conditions, monitoring checklist, and sourced live prices or explicit missing-data notes? |
Yes | Included above. |
| 20. If the thesis uses technical signals, are they framed as timing or confirmation inputs rather than the sole thesis? Does the article still work if the technical signal is removed? | Yes | RSI is a timing input only. |
| 21. Unless the user explicitly scoped the geography, did the research explicitly screen U.S., Japan, broader Asia, and Europe / UK lanes? | N/A | User explicitly scoped this run to U.S. market long. |
22. If the article uses Japan market as a lane or scope, did the screen explicitly prioritize local small-cap / mid-cap equities and names priced at or below JPY 800 / share? If the final Japan idea is an override, does the article clearly document both why compliant Japan candidates failed and why the higher-priced or larger-cap Japan idea still beat the best remaining non-Japan finalists? |
N/A | U.S.-only scope. |
23. If the user requested a live Substack finish, was the post actually created or updated in Substack, and was substack_submission_log.txt updated immediately with status, artifact state, URL, and blocker notes if any? |
N/A | Not requested. |
Sources
| # | Source | Use |
|---|---|---|
| 1 | FICO June 8, 2026 8-K exhibit on repurchase authorization, term loan, and ASR | $2.0B authorization, $1.5B term loan, $1.5B ASR, initial share delivery, and expected completion date. |
| 2 | Yahoo Finance chart API for FICO, checked in this run |
Current and recent prices, volumes, and 52-week range. |
| 3 | FICO Q2 FY2026 earnings release, filed April 28, 2026 | Revenue, segment growth, cash flow, free cash flow, and updated FY2026 guidance. |
| 4 | Innovative Industrial Properties June 15, 2026 8-K on exchangeable notes | Runner-up note size, exchange price, and share repurchase facts. |
| 5 | SEC company facts API for Fair Isaac Corporation, checked in this run | March 31 cash, debt, shares outstanding, and equity facts from FICO's filed 10-Q taxonomy. |
| 6 | BitGo June 17, 2026 8-K on $50M buyback | Runner-up buyback size, discretionary terms, and funding statement. |
| 7 | BitGo Q1 2026 earnings 8-K exhibit, filed May 13, 2026 | Runner-up operating context, including Q1 revenue and adjusted EBITDA. |
| 8 | Yahoo Finance chart API for IIPR, checked in this run |
Runner-up current price and recent trading range. |
| 9 | Yahoo Finance chart API for BTGO, checked in this run |
Runner-up current price, one-day move, and 52-week range. |
Illustration Prompt
Create a realistic, high-value, high-end elite, beautiful master editorial cover image for The Mispricing Desk about FICO in June 2026. Set the scene inside a severe credit bureau control room at night, with glass walls, muted data terminals, and an institutional bond-desk atmosphere. In the foreground, place a heavy black debt ledger stamped
TERM LOAN $1.5Bon one side and a precise share-count machine on the other side pulling certificates marked1,055,100 sharesinto a polished steel slot labeledASR. A clean ticker plaque should readFICO $1,126.84, with a smaller noteFY2026 non-GAAP EPS $40.45and a calendar tabASR by 2026-09-30. The visual tension should be clear: the market stares at leverage while the denominator quietly shrinks. Mood: forensic, expensive, skeptical, and exact, like a Bloomberg Markets or Barron's feature cover. Palette: graphite, cold blue glass, ivory filing paper, brushed steel, and one restrained red risk accent. Avoid generic green arrows, Wall Street bull imagery, cartoon credit cards, or glowing AI cliches. Include a subtle but clear watermark or engraved text readingThe Mispricing Desk.